ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,115
-0,19%
Bitcoin
66 640,05
0,68%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Sesen Bio Inc (SESN)

  7. Sesen Bio Inc (SESN) Actualités

SESN

Sesen Bio (SESN)

Sesen Bio Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SESN
DateHeureSourceTitreSymboleSociété
10/08/202313h30PR Newswire (US)Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:SESNSesen Bio Inc
06/03/202318h41Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:SESNSesen Bio Inc
06/03/202318h35Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SESNSesen Bio Inc
03/03/202317h07Edgar (US Regulatory)Sec Staff Action/letter (sec Staff)NASDAQ:SESNSesen Bio Inc
02/03/202317h32Business WireSesen Bio Stockholders Approve Merger with Carisma TherapeuticsNASDAQ:SESNSesen Bio Inc
28/02/202314h03Edgar (US Regulatory)Annual Report (10-k)NASDAQ:SESNSesen Bio Inc
28/02/202314h00Business WireSesen Bio Reports Fourth Quarter and Full-Year 2022 Financial ResultsNASDAQ:SESNSesen Bio Inc
21/02/202315h00Business WireLeading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With CarismaNASDAQ:SESNSesen Bio Inc
16/02/202323h06Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:SESNSesen Bio Inc
16/02/202322h42Business WireLeading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special MeetingNASDAQ:SESNSesen Bio Inc
16/02/202314h00Business WireSesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending MergerNASDAQ:SESNSesen Bio Inc
15/02/202322h55Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:SESNSesen Bio Inc
15/02/202314h00Business WireBML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma TherapeuticsNASDAQ:SESNSesen Bio Inc
14/02/202322h40Edgar (US Regulatory)Registration Pursuant to Securities Act Rule 462(b) of up to an Additional 20% of Securities for an Offering That Was Registered on a Form S-4 (s-4mef)NASDAQ:SESNSesen Bio Inc
14/02/202314h00Business WireSesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending MergerNASDAQ:SESNSesen Bio Inc
09/02/202318h10Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:SESNSesen Bio Inc
02/02/202322h30Business WireSesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics MergerNASDAQ:SESNSesen Bio Inc
30/01/202314h00Business WireSesen Bio Receives NASDAQ Delisting NoticeNASDAQ:SESNSesen Bio Inc
26/01/202314h00Business WireSesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of StockholdersNASDAQ:SESNSesen Bio Inc
25/01/202316h36Business WireInvestor Group Issues Letter to the Boards of Sesen Bio and Carisma Rejecting Their Apparent Attempt to Purchase Merger SupportNASDAQ:SESNSesen Bio Inc
20/01/202312h02Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:SESNSesen Bio Inc
19/01/202322h28Business WireSesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma TherapeuticsNASDAQ:SESNSesen Bio Inc
05/01/202314h00Business WireInvestor Group Issues Letter to Sesen Bio’s Board of Directors Regarding Intent to Vote AGAINST Proposed Carisma MergerNASDAQ:SESNSesen Bio Inc
04/01/202314h00Business WireSesen Bio Reiterates Confidence in Pending Merger with Carisma TherapeuticsNASDAQ:SESNSesen Bio Inc
03/01/202314h00Business WireInvestor Group Reiterates Intent to Vote AGAINST Sesen Bio’s Value-Destructive Merger with CarismaNASDAQ:SESNSesen Bio Inc
29/12/202222h33Business WireSesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending MergerNASDAQ:SESNSesen Bio Inc
22/11/202212h02Edgar (US Regulatory)Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a)NASDAQ:SESNSesen Bio Inc
07/11/202214h00Business WireSesen Bio Reports Third Quarter 2022 Financial Results and Business UpdateNASDAQ:SESNSesen Bio Inc
14/10/202223h10Edgar (US Regulatory)Securities Registration: Business Combination (s-4)NASDAQ:SESNSesen Bio Inc
21/09/202214h00Business WireSesen Bio and Carisma Therapeutics Announce Merger AgreementNASDAQ:SESNSesen Bio Inc
 Showing the most relevant articles for your search:NASDAQ:SESN

Dernières Valeurs Consultées

EU
ML
Michelin
NYSE
KO
Coca Cola
NYSE
DIS
Walt Disney
EU
AI
Air Liquide
EU
HO
Thales
EU
VK
Vallourec
EU
VIV
Vivendi
EU
BN
Danone
NASDAQ
GOOGL
Alphabet
EU
CS
Axa
EU
PX1
CAC 40
NASDAQ
NVDA
NVIDIA
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés